-
1
-
-
77449140027
-
Current issues in the treatment of type 2 diabetes. Overview of newer agents: Where treatment is going
-
DeFronzo RA. Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going. Am J Med 2010. 123:S38-S48.
-
(2010)
Am J Med
, vol.123
-
-
Defronzo, R.A.1
-
2
-
-
34249682591
-
Beta-cell failure in diabetes and preservation by clinical treatment
-
Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007 28:187-218.
-
(2007)
Endocr Rev
, vol.28
, pp. 187-218
-
-
Wajchenberg, B.L.1
-
3
-
-
0037784011
-
GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine
-
Mortensen K, Christensen LL, Holst JJ, Orskov C. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Pept 2003. 114:189-196.
-
(2003)
Regul Pept
, vol.114
, pp. 189-196
-
-
Mortensen, K.1
Christensen, L.L.2
Holst, J.J.3
Orskov, C.4
-
4
-
-
77953065317
-
Molecular mechanisms underlying nutrient-stimulated incretin secretion
-
Parker HE, Reimann F, Gribble FM. Molecular mechanisms underlying nutrient-stimulated incretin secretion. Expert Rev Mol Med 2010. 12:e1.
-
(2010)
Expert Rev Mol Med
, vol.12
-
-
Parker, H.E.1
Reimann, F.2
Gribble, F.M.3
-
5
-
-
33746467477
-
The glucagon-like peptides: Pleiotropic regulators of nutrient homeostasis
-
Brubaker PL. The glucagon-like peptides: pleiotropic regulators of nutrient homeostasis. Ann N Y Acad Sci 2006. 1070:10-26.
-
(2006)
Ann N Y Acad Sci
, vol.1070
, pp. 10-26
-
-
Brubaker, P.L.1
-
6
-
-
77951793008
-
Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired betacell function?
-
Meier JJ, Nauck MA. Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired betacell function? Diabetes 2010. 59:1117-1125.
-
(2010)
Diabetes
, vol.59
, pp. 1117-1125
-
-
Meier, J.J.1
Nauck, M.A.2
-
7
-
-
1842855423
-
Incretins, insulin secretion and type 2 diabetes mellitus
-
Vilsboll T, Holst JJ. Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia 2004. 47:357-366.
-
(2004)
Diabetologia
, vol.47
, pp. 357-366
-
-
Vilsboll, T.1
Holst, J.J.2
-
8
-
-
0001095690
-
Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients
-
Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001. 50:609-613.
-
(2001)
Diabetes
, vol.50
, pp. 609-613
-
-
Vilsboll, T.1
Krarup, T.2
Deacon, C.F.3
Madsbad, S.4
Holst, J.J.5
-
9
-
-
40949090627
-
Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance
-
Vollmer K, Holst JJ, Baller B, Ellrichmann M, Nauck MA, Schmidt WE, Meier JJ. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 2008. 57:678-687.
-
(2008)
Diabetes
, vol.57
, pp. 678-687
-
-
Vollmer, K.1
Holst, J.J.2
Baller, B.3
Ellrichmann, M.4
Nauck, M.A.5
Schmidt, W.E.6
Meier, J.J.7
-
10
-
-
0024397993
-
The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus
-
Jones IR, Owens DR, Luzio S, Williams S, Hayes TM. The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1989. 32:668-677.
-
(1989)
Diabetologia
, vol.32
, pp. 668-677
-
-
Jones, I.R.1
Owens, D.R.2
Luzio, S.3
Williams, S.4
Hayes, T.M.5
-
11
-
-
0036373430
-
Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients
-
Vilsboll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 2002. 45:1111-1119.
-
(2002)
Diabetologia
, vol.45
, pp. 1111-1119
-
-
Vilsboll, T.1
Krarup, T.2
Madsbad, S.3
Holst, J.J.4
-
12
-
-
0027391607
-
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus
-
Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993. 91:301-307.
-
(1993)
J Clin Invest
, vol.91
, pp. 301-307
-
-
Nauck, M.A.1
Heimesaat, M.M.2
Orskov, C.3
Holst, J.J.4
Ebert, R.5
Creutzfeldt, W.6
-
13
-
-
0035512742
-
Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes
-
Meier JJ, Hücking K, Holst JJ, Deacon CF, Schmiegel WH, Nauck MA. Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes 2001. 50:2497-2504.
-
(2001)
Diabetes
, vol.50
, pp. 2497-2504
-
-
Meier, J.J.1
Hücking, K.2
Holst, J.J.3
Deacon, C.F.4
Schmiegel, W.H.5
Nauck, M.A.6
-
14
-
-
34249724553
-
Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: Possible contribution to impaired incretin effects in diabetes
-
Xu G, Kaneto H, Laybutt DR, Duvivier-Kali VF, Trivedi N, Suzuma K, King GL, Weir GC, Bonner-Weir S. Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes. Diabetes 2007. 56:1551-1558.
-
(2007)
Diabetes
, vol.56
, pp. 1551-1558
-
-
Xu, G.1
Kaneto, H.2
Laybutt, D.R.3
Duvivier-Kali, V.F.4
Trivedi, N.5
Suzuma, K.6
King, G.L.7
Weir, G.C.8
Bonner-Weir, S.9
-
15
-
-
0030876081
-
The pathogenesis of NIDDM involves a defective expression of the GIP receptor. receptor
-
Holst JJ, Gromada J, Nauck MA. The pathogenesis of NIDDM involves a defective expression of the GIP receptor. receptor. Diabetologia 1997. 40:984-986.
-
(1997)
Diabetologia
, vol.40
, pp. 984-986
-
-
Holst, J.J.1
Gromada, J.2
Nauck, M.A.3
-
16
-
-
10544249875
-
Identification of two missense mutations in the GIP receptor gene: A functional study and association analysis with NIDDM: No evidence of association with Japanese NIDDM subjects
-
Kubota A, Yamada Y, Hayami T, Yasuda K, Someya Y, Ihara Y, Kagimoto S, Watanabe R, Taminato T, Tsuda K, Seino Y. Identification of two missense mutations in the GIP receptor gene: a functional study and association analysis with NIDDM: no evidence of association with Japanese NIDDM subjects. Diabetes 1996. 45:1701-1705.
-
(1996)
Diabetes
, vol.45
, pp. 1701-1705
-
-
Kubota, A.1
Yamada, Y.2
Hayami, T.3
Yasuda, K.4
Someya, Y.5
Ihara, Y.6
Kagimoto, S.7
Watanabe, R.8
Taminato, T.9
Tsuda, K.10
Seino, Y.11
-
17
-
-
0034880655
-
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
-
Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, Holst JJ. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001. 86:3717-3723.
-
(2001)
J Clin Endocrinol Metab
, vol.86
, pp. 3717-3723
-
-
Toft-Nielsen, M.B.1
Damholt, M.B.2
Madsbad, S.3
Hilsted, L.M.4
Hughes, T.E.5
Michelsen, B.K.6
Holst, J.J.7
-
18
-
-
0026027919
-
Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine
-
Orskov C, Jeppesen J, Madsbad S, Holst JJ. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest 1991. 87:415-423.
-
(1991)
J Clin Invest
, vol.87
, pp. 415-423
-
-
Orskov, C.1
Jeppesen, J.2
Madsbad, S.3
Holst, J.J.4
-
19
-
-
0037312821
-
The influence of GLP-1 on glucose-stimulated insulin secretion: Effects on beta-cell sensitivity in type 2 and nondiabetic subjects
-
Kjems LL, Holst JJ, Volund A, Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 2003. 52:380-386.
-
(2003)
Diabetes
, vol.52
, pp. 380-386
-
-
Kjems, L.L.1
Holst, J.J.2
Volund, A.3
Madsbad, S.4
-
20
-
-
0030068620
-
Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: Effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients
-
Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 1996. 81:327-332.
-
(1996)
J Clin Endocrinol Metab
, vol.81
, pp. 327-332
-
-
Willms, B.1
Werner, J.2
Holst, J.J.3
Orskov, C.4
Creutzfeldt, W.5
Nauck, M.A.6
-
21
-
-
0037667613
-
Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes
-
Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE, Nauck MA. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 2003. 88:2719-2725.
-
(2003)
J Clin Endocrinol Metab
, vol.88
, pp. 2719-2725
-
-
Meier, J.J.1
Gallwitz, B.2
Salmen, S.3
Goetze, O.4
Holst, J.J.5
Schmidt, W.E.6
Nauck, M.A.7
-
22
-
-
78650753885
-
Incretin-based therapies for type 2 diabetes mellitus: Properties, functions, and clinical implications
-
Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 2011. 124(1 Suppl): S3-S18.
-
(2011)
Am J Med
, vol.124
, Issue.1 SUPPL.
-
-
Nauck, M.A.1
-
23
-
-
77951793008
-
Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired betacell function?
-
Meier JJ, Nauck MA. Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired betacell function? Diabetes 2010. 59:1117-1125.
-
(2010)
Diabetes
, vol.59
, pp. 1117-1125
-
-
Meier, J.J.1
Nauck, M.A.2
-
24
-
-
34547586659
-
Reduced incretin effect in type 2 diabetes: Cause or consequence of the diabetic state?
-
Knop FK, Vilsboll T, Hojberg PV, Larsen S, Madsbad S, Volund A, Holst JJ, Krarup T. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes 2007. 56:1951-1959.
-
(2007)
Diabetes
, vol.56
, pp. 1951-1959
-
-
Knop, F.K.1
Vilsboll, T.2
Hojberg, P.V.3
Larsen, S.4
Madsbad, S.5
Volund, A.6
Holst, J.J.7
Krarup, T.8
-
25
-
-
2342642148
-
Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance
-
Rask E, Olsson T, Söderberg S, Holst JJ, Tura A, Pacini G, Ahren B. Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance. Metabolism 2004. 53:624-631.
-
(2004)
Metabolism
, vol.53
, pp. 624-631
-
-
Rask, E.1
Olsson, T.2
Söderberg, S.3
Holst, J.J.4
Tura, A.5
Pacini, G.6
Ahren, B.7
-
26
-
-
0030845083
-
Reduced gastric inhibitory polypeptide but normal glucagon-like peptide 1 response to oral glucose in postmenopausal women with impaired glucose tolerance
-
Ahren B, Larsson H, Holst JJ. Reduced gastric inhibitory polypeptide but normal glucagon-like peptide 1 response to oral glucose in postmenopausal women with impaired glucose tolerance. Eur J Endocrinol 1997. 137:127-131.
-
(1997)
Eur J Endocrinol
, vol.137
, pp. 127-131
-
-
Ahren, B.1
Larsson, H.2
Holst, J.J.3
-
27
-
-
33845383843
-
Impact of incretin hormones on beta-cell function in subjects with normal or impaired glucose tolerance
-
Muscelli E, Mari A, Natali A, Astiarraga BD, Camastra S, Frascerra S, Holst JJ, Ferrannini E. Impact of incretin hormones on beta-cell function in subjects with normal or impaired glucose tolerance. Am J Physiol Endocrinol Metab 2006. 291:E1144-E1150.
-
(2006)
Am J Physiol Endocrinol Metab
, vol.291
-
-
Muscelli, E.1
Mari, A.2
Natali, A.3
Astiarraga, B.D.4
Camastra, S.5
Frascerra, S.6
Holst, J.J.7
Ferrannini, E.8
-
28
-
-
48449093468
-
Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients
-
Muscelli E, Mari A, Casolaro A, Camastra S, Seghieri G, Gastaldelli A, Holst JJ, Ferrannini E. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008. 57:1340-1348.
-
(2008)
Diabetes
, vol.57
, pp. 1340-1348
-
-
Muscelli, E.1
Mari, A.2
Casolaro, A.3
Camastra, S.4
Seghieri, G.5
Gastaldelli, A.6
Holst, J.J.7
Ferrannini, E.8
-
29
-
-
3042832070
-
Elevated plasma glucose-dependent insulinotropic polypeptide associates with hyperinsulinemia in impaired glucose tolerance
-
Theodorakis MJ, Carlson O, Muller DC, Egan JM. Elevated plasma glucose-dependent insulinotropic polypeptide associates with hyperinsulinemia in impaired glucose tolerance. Diabetes Care 2004. 27:1692-1698.
-
(2004)
Diabetes Care
, vol.27
, pp. 1692-1698
-
-
Theodorakis, M.J.1
Carlson, O.2
Muller, D.C.3
Egan, J.M.4
-
30
-
-
33845405222
-
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
-
Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006. 355:2427-2443.
-
(2006)
N Engl J Med
, vol.355
, pp. 2427-2443
-
-
Kahn, S.E.1
Haffner, S.M.2
Heise, M.A.3
Herman, W.H.4
Holman, R.R.5
Jones, N.P.6
Kravitz, B.G.7
Lachin, J.M.8
O'Neill, M.C.9
Zinman, B.10
Viberti, G.11
-
31
-
-
64749100501
-
Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
-
Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009. 32:193-203.
-
(2009)
Diabetes Care
, vol.32
, pp. 193-203
-
-
Nathan, D.M.1
Buse, J.B.2
Davidson, M.B.3
Ferrannini, E.4
Holman, R.R.5
Sherwin, R.6
Zinman, B.7
-
32
-
-
77955657408
-
Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis
-
Schernthaner G, Barnett AH, Betteridge DJ, Carmena R, Ceriello A, Charbonnel B, Hanefeld M, Lehmann R, Malecki MT, Nesto R, et al. Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia 2010. 53:1258-1269.
-
(2010)
Diabetologia
, vol.53
, pp. 1258-1269
-
-
Schernthaner, G.1
Barnett, A.H.2
Betteridge, D.J.3
Carmena, R.4
Ceriello, A.5
Charbonnel, B.6
Hanefeld, M.7
Lehmann, R.8
Malecki, M.T.9
Nesto, R.10
-
33
-
-
60549097258
-
Targeting incretins in type 2 diabetes: Role of GLP-1 receptor agonists and DPP-4 inhibitors
-
Pratley RE, Gilbert M. Targeting incretins in type 2 diabetes: role of GLP-1 receptor agonists and DPP-4 inhibitors. Rev Diabet Stud 2008. 5(2):73-94.
-
(2008)
Rev Diabet Stud
, vol.5
, Issue.2
, pp. 73-94
-
-
Pratley, R.E.1
Gilbert, M.2
-
34
-
-
79959774265
-
Therapy in the early stage: Incretins
-
Cernea S, Raz I. Therapy in the early stage: incretins. Diabetes Care 2011. 34(Suppl 2):S264-S271.
-
(2011)
Diabetes Care
, vol.34
, Issue.SUPPL. 2
-
-
Cernea, S.1
Raz, I.2
-
35
-
-
0034507515
-
Glucagon-like peptide-1: A major regulator of pancreatic beta-cell function
-
Perfetti R, Merkel P. Glucagon-like peptide-1: a major regulator of pancreatic beta-cell function. Eur J Endocrinol 2000. 143:717-725.
-
(2000)
Eur J Endocrinol
, vol.143
, pp. 717-725
-
-
Perfetti, R.1
Merkel, P.2
-
36
-
-
0036323269
-
Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells
-
Abraham EJ, Leech CA, Lin JC, Zulewski H, Habener JF. Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells. Endocrinology 2002. 143:3152-3161.
-
(2002)
Endocrinology
, vol.143
, pp. 3152-3161
-
-
Abraham, E.J.1
Leech, C.A.2
Lin, J.C.3
Zulewski, H.4
Habener, J.F.5
-
37
-
-
0033513455
-
Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats
-
Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999. 48:2270-2276.
-
(1999)
Diabetes
, vol.48
, pp. 2270-2276
-
-
Xu, G.1
Stoffers, D.A.2
Habener, J.F.3
Bonner-Weir, S.4
-
38
-
-
23844463766
-
Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes
-
Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, Deacon CF, Holst JJ, Foley JE. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metabm 2005. 90:4888-4894.
-
(2005)
J Clin Endocrinol Metabm
, vol.90
, pp. 4888-4894
-
-
Mari, A.1
Sallas, W.M.2
He, Y.L.3
Watson, C.4
Ligueros-Saylan, M.5
Dunning, B.E.6
Deacon, C.F.7
Holst, J.J.8
Foley, J.E.9
-
39
-
-
27744541052
-
Exenatide augments first-and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes
-
Fehse F, Trautmann M, Holst JJ, Halseth AE, Nanayakkara N, Nielsen LL, Fineman MS, Kim DD, Nauck MA. Exenatide augments first-and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2005. 90:5991-5997.
-
(2005)
J Clin Endocrinol Metab
, vol.90
, pp. 5991-5997
-
-
Fehse, F.1
Trautmann, M.2
Holst, J.J.3
Halseth, A.E.4
Nanayakkara, N.5
Nielsen, L.L.6
Fineman, M.S.7
Kim, D.D.8
Nauck, M.A.9
-
40
-
-
75749094777
-
Preclinical and clinical data on extraglycemic effects of GLP-1 receptor agonists
-
Gallwitz B. Preclinical and clinical data on extraglycemic effects of GLP-1 receptor agonists. Rev Diabet Stud 2009. 6(4):247-259.
-
(2009)
Rev Diabet Stud
, vol.6
, Issue.4
, pp. 247-259
-
-
Gallwitz, B.1
-
41
-
-
34248223285
-
Biology of incretins: GLP-1 and GIP
-
Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007. 132:2131-2157.
-
(2007)
Gastroenterology
, vol.132
, pp. 2131-2157
-
-
Baggio, L.L.1
Drucker, D.J.2
-
42
-
-
0030667056
-
Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans
-
Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997. 273:E981-E988.
-
(1997)
Am J Physiol
, vol.273
-
-
Nauck, M.A.1
Niedereichholz, U.2
Ettler, R.3
Holst, J.J.4
Orskov, C.5
Ritzel, R.6
Schmiegel, W.H.7
-
43
-
-
67649476077
-
Incretin therapies: Effects beyond glycemic control
-
Mudaliar S, Henry RR. Incretin therapies: effects beyond glycemic control. Eur J Intern Med 2009. 20:S319-S328.
-
(2009)
Eur J Intern Med
, vol.20
-
-
Mudaliar, S.1
Henry, R.R.2
-
44
-
-
12144260853
-
Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury
-
Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005. 54:146-151.
-
(2005)
Diabetes
, vol.54
, pp. 146-151
-
-
Bose, A.K.1
Mocanu, M.M.2
Carr, R.D.3
Brand, C.L.4
Yellon, D.M.5
-
45
-
-
4344605042
-
Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy
-
Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L, Stolarski C, Shen YT, Shannon RP. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004. 110:955-961.
-
(2004)
Circulation
, vol.110
, pp. 955-961
-
-
Nikolaidis, L.A.1
Elahi, D.2
Hentosz, T.3
Doverspike, A.4
Huerbin, R.5
Zourelias, L.6
Stolarski, C.7
Shen, Y.T.8
Shannon, R.P.9
-
46
-
-
33847645068
-
Impaired fasting glucose and impaired glucose tolerance: Implications for care
-
Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, Zinman B. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007. 30:753-759.
-
(2007)
Diabetes Care
, vol.30
, pp. 753-759
-
-
Nathan, D.M.1
Davidson, M.B.2
Defronzo, R.A.3
Heine, R.J.4
Henry, R.R.5
Pratley, R.6
Zinman, B.7
-
48
-
-
0030935652
-
Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerances
-
The Da Qing IGT and Diabetes Study
-
Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerances. The Da Qing IGT and Diabetes Study. Diabetes Care 1997. 20(4):537-544.
-
(1997)
Diabetes Care
, vol.20
, Issue.4
, pp. 537-544
-
-
Pan, X.R.1
Li, G.W.2
Hu, Y.H.3
Wang, J.X.4
Yang, W.Y.5
An, Z.X.6
Hu, Z.X.7
Lin, J.8
Xiao, J.Z.9
Cao, H.B.10
-
49
-
-
0037034257
-
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
-
Diabetes Prevention Program Research Group
-
Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002. 346:393-403.
-
(2002)
N Engl J Med
, vol.346
, pp. 393-403
-
-
-
50
-
-
0037530417
-
Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: Results from a randomized clinical trial
-
Lindstrom J, Eriksson JG, Valle TT, Aunola S, Cepaitis Z, Hakumäki M, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: Results from a randomized clinical trial. J Am Soc Nephrol 2003. 14(7 Suppl 2):S108-S113.
-
(2003)
J Am Soc Nephrol
, vol.14
, Issue.7 SUPPL. 2
-
-
Lindstrom, J.1
Eriksson, J.G.2
Valle, T.T.3
Aunola, S.4
Cepaitis, Z.5
Hakumäki, M.6
Hämäläinen, H.7
Ilanne-Parikka, P.8
Keinänen-Kiukaanniemi, S.9
Laakso, M.10
-
51
-
-
0036724346
-
Preservation of pancreatic-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high risk Hispanic women
-
Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP. Preservation of pancreatic-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high risk Hispanic women. Diabetes 2002. 51(9):2796-2803.
-
(2002)
Diabetes
, vol.51
, Issue.9
, pp. 2796-2803
-
-
Buchanan, T.A.1
Xiang, A.H.2
Peters, R.K.3
Kjos, S.L.4
Marroquin, A.5
Goico, J.6
Ochoa, C.7
Tan, S.8
Berkowitz, K.9
Hodis, H.N.10
Azen, S.P.11
-
52
-
-
33748748206
-
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial
-
Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. Lancet 2006. 368(9541):1096-1105.
-
(2006)
Lancet
, vol.368
, Issue.9541
, pp. 1096-1105
-
-
Gerstein, H.C.1
Yusuf, S.2
Bosch, J.3
Pogue, J.4
Sheridan, P.5
Dinccag, N.6
Hanefeld, M.7
Hoogwerf, B.8
Laakso, M.9
Mohan, V.10
Shaw, J.11
Zinman, B.12
Holman, R.R.13
-
53
-
-
33749590988
-
Effect of ramipril on the incidence of diabetes
-
Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, Diaz R, Avezum A, Lanas F, Probstfield J, Fodor G, Holman RR. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006. 355(15):1551-1562.
-
(2006)
N Engl J Med
, vol.355
, Issue.15
, pp. 1551-1562
-
-
Bosch, J.1
Yusuf, S.2
Gerstein, H.C.3
Pogue, J.4
Sheridan, P.5
Dagenais, G.6
Diaz, R.7
Avezum, A.8
Lanas, F.9
Probstfield, J.10
Fodor, G.11
Holman, R.R.12
-
54
-
-
0038455703
-
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance
-
The STOP-NIDDM trial
-
Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The STOP-NIDDM trial. JAMA 2003. 290(4):486-494.
-
(2003)
JAMA
, vol.290
, Issue.4
, pp. 486-494
-
-
Chiasson, J.L.1
Josse, R.G.2
Gomis, R.3
Hanefeld, M.4
Karasik, A.5
Laakso, M.6
-
55
-
-
0042195062
-
Efficacy of acarbose in Chinese subjects with impaired glucose tolerance
-
Pan CY, Gao U, Chen JW, Luo BY, Fu ZZ, Lu JM, Guo XH, Cheng H. Efficacy of acarbose in Chinese subjects with impaired glucose tolerance. Diabetes Res Clin Pract 2003. 61(3):183-190.
-
(2003)
Diabetes Res Clin Pract
, vol.61
, Issue.3
, pp. 183-190
-
-
Pan, C.Y.1
Gao, U.2
Chen, J.W.3
Luo, B.Y.4
Fu, Z.Z.5
Lu, J.M.6
Guo, X.H.7
Cheng, H.8
-
57
-
-
77951453096
-
Effect of valsartan on the incidence of diabetes and cardiovascular events
-
McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010. 362(16):1477-1490.
-
(2010)
N Engl J Med
, vol.362
, Issue.16
, pp. 1477-1490
-
-
McMurray, J.J.1
Holman, R.R.2
Haffner, S.M.3
Bethel, M.A.4
Holzhauer, B.5
Hua, T.A.6
Belenkov, Y.7
Boolell, M.8
Buse, J.B.9
Buckley, B.M.10
-
58
-
-
77951473452
-
Effect of nateglinide on the incidence of diabetes and cardiovascular events
-
Holman RR, Haffner SM, McMurray JJ, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010. 362(16):1463-1476.
-
(2010)
N Engl J Med
, vol.362
, Issue.16
, pp. 1463-1476
-
-
Holman, R.R.1
Haffner, S.M.2
McMurray, J.J.3
Bethel, M.A.4
Holzhauer, B.5
Hua, T.A.6
Belenkov, Y.7
Boolell, M.8
Buse, J.B.9
Buckley, B.M.10
-
59
-
-
77956090389
-
Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without prediabetes
-
Rosenstock J, Klaff LJ, Schwartz S, Northrup J, Holcombe JH, Wilhelm K, Trautmann M. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without prediabetes. Diabetes Care 2010. 33:1173-1175.
-
(2010)
Diabetes Care
, vol.33
, pp. 1173-1175
-
-
Rosenstock, J.1
Klaff, L.J.2
Schwartz, S.3
Northrup, J.4
Holcombe, J.H.5
Wilhelm, K.6
Trautmann, M.7
-
60
-
-
38149110484
-
The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose
-
Utzschneider KM, Tong J, Montgomery B, Udayasankar J, Gerchman F, Marcovina SM, Watson CE, Ligueros-Saylan MA, Foley JE, Holst JJ, Deacon CF, Kahn SE. The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care 2008. 31:108-113.
-
(2008)
Diabetes Care
, vol.31
, pp. 108-113
-
-
Utzschneider, K.M.1
Tong, J.2
Montgomery, B.3
Udayasankar, J.4
Gerchman, F.5
Marcovina, S.M.6
Watson, C.E.7
Ligueros-Saylan, M.A.8
Foley, J.E.9
Holst, J.J.10
Deacon, C.F.11
Kahn, S.E.12
-
61
-
-
77954866977
-
The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose
-
Bock G, Man CD, Micheletto F, Basu R, Rn PD, Laugen J, Deacon CF, Holst JJ, Toffolo G, Cobelli C, Rizza RA, Vella A. The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose. Clin Endocrinol (Oxf) 2010. 73:189-196.
-
(2010)
Clin Endocrinol (Oxf)
, vol.73
, pp. 189-196
-
-
Bock, G.1
Man, C.D.2
Micheletto, F.3
Basu, R.4
Rn, P.D.5
Laugen, J.6
Deacon, C.F.7
Holst, J.J.8
Toffolo, G.9
Cobelli, C.10
Rizza, R.A.11
Vella, A.12
-
62
-
-
38149096290
-
Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance
-
Rosenstock J, Foley JE, Rendell M, Landin-Olsson M, Holst JJ, Deacon CF, Rochotte E, Baron MA. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care 2008. 31:30-35.
-
(2008)
Diabetes Care
, vol.31
, pp. 30-35
-
-
Rosenstock, J.1
Foley, J.E.2
Rendell, M.3
Landin-Olsson, M.4
Holst, J.J.5
Deacon, C.F.6
Rochotte, E.7
Baron, M.A.8
-
63
-
-
84855539606
-
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan
-
Handelsman Y, Mechanick JI, Blonde L, Grunberger G, Bloomgarden ZT, Bray GA, Dagogo-Jack S, Davidson JA, Einhorn D, Ganda O, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract 2011. 17(Suppl 2):1-53.
-
(2011)
Endocr Pract
, vol.17
, Issue.SUPPL. 2
, pp. 1-53
-
-
Handelsman, Y.1
Mechanick, J.I.2
Blonde, L.3
Grunberger, G.4
Bloomgarden, Z.T.5
Bray, G.A.6
Dagogo-Jack, S.7
Davidson, J.A.8
Einhorn, D.9
Ganda, O.10
-
64
-
-
54049117795
-
-
The National Collaborating Centre for Chronic Conditions, National Clinical Guideline for Management, in Primary and Secondary Care (update). Royal College of Physicians, London
-
The National Collaborating Centre for Chronic Conditions. Type 2 diabetes. National Clinical Guideline for Management in Primary and Secondary Care (update). Royal College of Physicians, London, 2008.
-
(2008)
Type 2 Diabetes
-
-
-
65
-
-
58949090850
-
Update on the Canadian Diabetes Association 2008 clinical practice guidelines
-
Bhattacharyya OK, Estey EA, Cheng AY. Update on the Canadian Diabetes Association 2008 clinical practice guidelines. Can Fam Physician 2009. 55:39-43.
-
(2009)
Can Fam Physician
, vol.55
, pp. 39-43
-
-
Bhattacharyya, O.K.1
Estey, E.A.2
Cheng, A.Y.3
-
66
-
-
78449274342
-
Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1
-
Migoya EM, Bergeron R, Miller JL, Snyder RN, Tanen M, Hilliard D, Weiss B, Larson P, Gutierrez M, Jiang G, et al. Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther 2010. 88:801-808.
-
(2010)
Clin Pharmacol Ther
, vol.88
, pp. 801-808
-
-
Migoya, E.M.1
Bergeron, R.2
Miller, J.L.3
Snyder, R.N.4
Tanen, M.5
Hilliard, D.6
Weiss, B.7
Larson, P.8
Gutierrez, M.9
Jiang, G.10
-
67
-
-
78951476273
-
Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-alpha in mice
-
Maida A, Lamont BJ, Cao X, Drucker DJ. Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-alpha in mice. Diabetologia 2011. 54:339-349.
-
(2011)
Diabetologia
, vol.54
, pp. 339-349
-
-
Maida, A.1
Lamont, B.J.2
Cao, X.3
Drucker, D.J.4
-
68
-
-
67649233262
-
The individualized target HbA1c: A new method for improving macrovascular risk and glycemia without hypoglycemia and weight gain
-
Eldor R, Raz I. The individualized target HbA1c: a new method for improving macrovascular risk and glycemia without hypoglycemia and weight gain. Rev Diabet Stud 2009. 6(1):6-12.
-
(2009)
Rev Diabet Stud
, vol.6
, Issue.1
, pp. 6-12
-
-
Eldor, R.1
Raz, I.2
-
69
-
-
34447267513
-
Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis
-
Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007. 298:194-206.
-
(2007)
JAMA
, vol.298
, pp. 194-206
-
-
Amori, R.E.1
Lau, J.2
Pittas, A.G.3
-
70
-
-
77954277563
-
A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes
-
Fakhoury WK, Lereun C, Wright D. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology 2010. 86:44-57.
-
(2010)
Pharmacology
, vol.86
, pp. 44-57
-
-
Fakhoury, W.K.1
Lereun, C.2
Wright, D.3
-
71
-
-
51549095571
-
Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study
-
Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008. 30:1448-1460.
-
(2008)
Clin Ther
, vol.30
, pp. 1448-1460
-
-
Moretto, T.J.1
Milton, D.R.2
Ridge, T.D.3
Macconell, L.A.4
Okerson, T.5
Wolka, A.M.6
Brodows, R.G.7
-
72
-
-
20544476444
-
Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: A dose-ranging study
-
Poon T, Nelson P, Shen L, Mihm M, Taylor K, Fineman M, Kim D. Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technol Ther 2005. 7:467-477.
-
(2005)
Diabetes Technol Ther
, vol.7
, pp. 467-477
-
-
Poon, T.1
Nelson, P.2
Shen, L.3
Mihm, M.4
Taylor, K.5
Fineman, M.6
Kim, D.7
-
73
-
-
47649094517
-
Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A doubleblind, randomized, controlled trial in Japanese patients with type 2 diabetes
-
Seino Y, Rasmussen MF, Zdravkovic M, Kaku K. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A doubleblind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008. 81:161-168.
-
(2008)
Diabetes Res Clin Pract
, vol.81
, pp. 161-168
-
-
Seino, Y.1
Rasmussen, M.F.2
Zdravkovic, M.3
Kaku, K.4
-
74
-
-
34249869806
-
Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes
-
Vilsboll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courreges JP, Verhoeven R, Buganova I, Madsbad S. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007. 30:1608-1610.
-
(2007)
Care
, vol.30
, pp. 1608-1610
-
-
Vilsboll, T.1
Zdravkovic, M.2
Le-Thi, T.3
Krarup, T.4
Schmitz, O.5
Courreges, J.P.6
Verhoeven, R.7
Buganova, I.8
Madsbad, S.9
-
75
-
-
59449101432
-
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): A randomised, 52-week, phase III, double-blind, paralleltreatment trial
-
Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, paralleltreatment trial. Lancet 2009. 373:473-481.
-
(2009)
Lancet
, vol.373
, pp. 473-481
-
-
Garber, A.1
Henry, R.2
Ratner, R.3
Garcia-Hernandez, P.A.4
Rodriguez-Pattzi, H.5
Olvera-Alvarez, I.6
Hale, P.M.7
Zdravkovic, M.8
Bode, B.9
-
76
-
-
33845472504
-
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes
-
Sitagliptin Study, 021 Group
-
Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE, Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006. 29:2632-2637.
-
(2006)
Diabetes Care
, vol.29
, pp. 2632-2637
-
-
Aschner, P.1
Kipnes, M.S.2
Lunceford, J.K.3
Sanchez, M.4
Mickel, C.5
Williams-Herman, D.E.6
-
77
-
-
34347219401
-
Sitagliptin Study 014 Investigators. Oncedaily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes
-
Hanefeld M, Herman GA, Wu M, Mickel C, Sanchez M, Stein PP. Sitagliptin Study 014 Investigators. Oncedaily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin 2007. 23:1329-1339.
-
(2007)
Curr Med Res Opin
, vol.23
, pp. 1329-1339
-
-
Hanefeld, M.1
Herman, G.A.2
Wu, M.3
Mickel, C.4
Sanchez, M.5
Stein, P.P.6
-
78
-
-
58049192811
-
Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea
-
Mohan V, Yang W, Son HY, Xu L, Noble L, Langdon RB, Amatruda JM, Stein PP, Kaufman KD. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract 2009. 83:106-116.
-
(2009)
Diabetes Res Clin Pract
, vol.83
, pp. 106-116
-
-
Mohan, V.1
Yang, W.2
Son, H.Y.3
Xu, L.4
Noble, L.5
Langdon, R.B.6
Amatruda, J.M.7
Stein, P.P.8
Kaufman, K.D.9
-
79
-
-
38349126264
-
Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes
-
Nonaka K, Kakikawa T, Sato A, Okuyama K, Fujimoto G, Kato N, Suzuki H, Hirayama Y, Ahmed T, Davies MJ, Stein PP. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008. 79:291-298.
-
(2008)
Diabetes Res Clin Pract
, vol.79
, pp. 291-298
-
-
Nonaka, K.1
Kakikawa, T.2
Sato, A.3
Okuyama, K.4
Fujimoto, G.5
Kato, N.6
Suzuki, H.7
Hirayama, Y.8
Ahmed, T.9
Davies, M.J.10
Stein, P.P.11
-
80
-
-
33847024333
-
Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes
-
Scott R, Wu M, Sanchez M, Stein P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007. 61:171-180.
-
(2007)
Int J Clin Pract
, vol.61
, pp. 171-180
-
-
Scott, R.1
Wu, M.2
Sanchez, M.3
Stein, P.4
-
81
-
-
33845489598
-
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus
-
Sitagliptin Study 023 Group
-
Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H. Sitagliptin Study 023 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006. 49:2564-2571.
-
(2006)
Diabetologia
, vol.49
, pp. 2564-2571
-
-
Raz, I.1
Hanefeld, M.2
Xu, L.3
Caria, C.4
Williams-Herman, D.5
Khatami, H.6
-
82
-
-
27744540889
-
Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: Vildagliptin (LAF237) dose response
-
Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005. 7:692-698.
-
(2005)
Diabetes Obes Metab
, vol.7
, pp. 692-698
-
-
Ristic, S.1
Byiers, S.2
Foley, J.3
Holmes, D.4
-
83
-
-
33847687205
-
Vildagliptin in drug-naïve patients with type 2 diabetes: A 24-week, double-blind, randomized, placebo-controlled, multiple-dose study
-
Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007. 39:218-223.
-
(2007)
Horm Metab Res
, vol.39
, pp. 218-223
-
-
Dejager, S.1
Razac, S.2
Foley, J.E.3
Schweizer, A.4
-
84
-
-
58349115426
-
Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus
-
Kikuchi M, Abe N, Kato M, Terao S, Mimori N, Tachibana H. Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2009. 83:233-240.
-
(2009)
Diabetes Res Clin Pract
, vol.83
, pp. 233-240
-
-
Kikuchi, M.1
Abe, N.2
Kato, M.3
Terao, S.4
Mimori, N.5
Tachibana, H.6
-
85
-
-
33846905487
-
Efficacy and tolerability of vildagliptin monotherapy in drugnaïve patients with type 2 diabetes
-
Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drugnaïve patients with type 2 diabetes. Diabetes Res Clin Pract 2007. 76:132-138.
-
(2007)
Diabetes Res Clin Pract
, vol.76
, pp. 132-138
-
-
Pi-Sunyer, F.X.1
Schweizer, A.2
Mills, D.3
Dejager, S.4
-
86
-
-
53549129604
-
Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia
-
Scherbaum WA, Schweizer A, Mari A, Nilsson PM, Lalanne G, Wang Y, Dunning BE, Foley JE. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 2008. 10:1114-1124.
-
(2008)
Diabetes Obes Metab
, vol.10
, pp. 1114-1124
-
-
Scherbaum, W.A.1
Schweizer, A.2
Mari, A.3
Nilsson, P.M.4
Lalanne, G.5
Wang, Y.6
Dunning, B.E.7
Foley, J.E.8
-
87
-
-
70349333861
-
Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes
-
Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. Curr Med Res Opin 2009. 25:2401-2411.
-
(2009)
Curr Med Res Opin
, vol.25
, pp. 2401-2411
-
-
Rosenstock, J.1
Aguilar-Salinas, C.2
Klein, E.3
Nepal, S.4
List, J.5
Chen, R.6
-
88
-
-
42149194313
-
Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes
-
Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 2008. 10:376-386.
-
(2008)
Diabetes Obes Metab
, vol.10
, pp. 376-386
-
-
Rosenstock, J.1
Sankoh, S.2
List, J.F.3
-
89
-
-
34548118796
-
Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with type 2 diabetes
-
Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with type 2 diabetes. Diabet Med 2007. 24:955-961.
-
(2007)
Diabet Med
, vol.24
, pp. 955-961
-
-
Schweizer, A.1
Couturier, A.2
Foley, J.E.3
Dejager, S.4
-
91
-
-
69849104533
-
Incretin-based therapy: How do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients?
-
Nauck M, Smith U. Incretin-based therapy: how do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients? Best Pract Res Clin Endocrinol Metab 2009. 23:513-523.
-
(2009)
Best Pract Res Clin Endocrinol Metab
, vol.23
, pp. 513-523
-
-
Nauck, M.1
Smith, U.2
-
92
-
-
65549124145
-
Exenatide: Clinical aspects of the first incretin-mimetic for the treatment of type 2 diabetes mellitus
-
Wajcberg E, Tavaria A. Exenatide: clinical aspects of the first incretin-mimetic for the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother 2009. 10:135-142.
-
(2009)
Expert Opin Pharmacother
, vol.10
, pp. 135-142
-
-
Wajcberg, E.1
Tavaria, A.2
-
93
-
-
18144401971
-
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformintreated patients with type 2 diabetes
-
DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformintreated patients with type 2 diabetes. Diabetes Care 2005. 28:1092-1100.
-
(2005)
Diabetes Care
, vol.28
, pp. 1092-1100
-
-
Defronzo, R.A.1
Ratner, R.E.2
Han, J.3
Kim, D.D.4
Fineman, M.S.5
Baron, A.D.6
-
94
-
-
62449169287
-
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (liraglutide effect and action in diabetes)-2 study
-
Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M, Matthews DR. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009. 32:84-90.
-
(2009)
Diabetes Care
, vol.32
, pp. 84-90
-
-
Nauck, M.1
Frid, A.2
Hermansen, K.3
Shah, N.S.4
Tankova, T.5
Mitha, I.H.6
Zdravkovic, M.7
Düring, M.8
Matthews, D.R.9
-
95
-
-
7444228521
-
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
-
Exenatide-113 Clinical Study Group
-
Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD, Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004. 27:2628-2635.
-
(2004)
Diabetes Care
, vol.27
, pp. 2628-2635
-
-
Buse, J.B.1
Henry, R.R.2
Han, J.3
Kim, D.D.4
Fineman, M.S.5
Baron, A.D.6
-
96
-
-
62449129181
-
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
-
Marre M, Shaw J, Brändle M, Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD, Colagiuri S. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009. 26:268-278.
-
(2009)
Diabet Med
, vol.26
, pp. 268-278
-
-
Marre, M.1
Shaw, J.2
Brändle, M.3
Bebakar, W.M.4
Kamaruddin, N.A.5
Strand, J.6
Zdravkovic, M.7
le Thi, T.D.8
Colagiuri, S.9
-
97
-
-
34247259577
-
The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: A randomized trial
-
Zinman B, Hoogwerf BJ, Duran Garcia S, Milton DR, Giaconia JM, Kim DD, Trautmann ME, Brodows RG. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007. 146:477-485.
-
(2007)
Ann Intern Med
, vol.146
, pp. 477-485
-
-
Zinman, B.1
Hoogwerf, B.J.2
Duran, G.S.3
Milton, D.R.4
Giaconia, J.M.5
Kim, D.D.6
Trautmann, M.E.7
Brodows, R.G.8
-
98
-
-
43449096512
-
Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes
-
Scott R, Loeys T, Davies MJ, Engel SS. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008. 10:959-969.
-
(2008)
Diabetes Obes Metab
, vol.10
, pp. 959-969
-
-
Scott, R.1
Loeys, T.2
Davies, M.J.3
Engel, S.S.4
-
99
-
-
33845476757
-
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
-
Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006. 29:2638-2643.
-
(2006)
Diabetes Care
, vol.29
, pp. 2638-2643
-
-
Charbonnel, B.1
Karasik, A.2
Liu, J.3
Wu, M.4
Meininger, G.5
-
100
-
-
34547660561
-
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes
-
Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007. 30:1979-1987.
-
(2007)
Diabetes Care
, vol.30
, pp. 1979-1987
-
-
Goldstein, B.J.1
Feinglos, M.N.2
Lunceford, J.K.3
Johnson, J.4
Williams-Herman, D.E.5
-
101
-
-
39749184723
-
Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes
-
Raz I, Chen Y, Wu M, Hussain S, Kaufman KD, Amatruda JM, Langdon RB, Stein PP, Alba M. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 2008. 24:537-550.
-
(2008)
Curr Med Res Opin
, vol.24
, pp. 537-550
-
-
Raz, I.1
Chen, Y.2
Wu, M.3
Hussain, S.4
Kaufman, K.D.5
Amatruda, J.M.6
Langdon, R.B.7
Stein, P.P.8
Alba, M.9
-
102
-
-
9444285818
-
Twelve-and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes
-
Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve-and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004. 27:2874-2880.
-
(2004)
Diabetes Care
, vol.27
, pp. 2874-2880
-
-
Ahren, B.1
Gomis, R.2
Standl, E.3
Mills, D.4
Schweizer, A.5
-
103
-
-
34147093268
-
Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin
-
Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007. 30:890-895.
-
(2007)
Diabetes Care
, vol.30
, pp. 890-895
-
-
Bosi, E.1
Camisasca, R.P.2
Collober, C.3
Rochotte, E.4
Garber, A.J.5
-
104
-
-
67949105103
-
Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy
-
Goodman M, Thurston H, Penman J. Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Horm Metab Res 2009. 41:368-373.
-
(2009)
Horm. Metab Res
, vol.41
, pp. 368-373
-
-
Goodman, M.1
Thurston, H.2
Penman, J.3
-
105
-
-
58149330590
-
Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy
-
Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahren B, Byiers S, Shao Q, Dejager S. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009. 11:157-166.
-
(2009)
Diabetes Obes Metab
, vol.11
, pp. 157-166
-
-
Ferrannini, E.1
Fonseca, V.2
Zinman, B.3
Matthews, D.4
Ahren, B.5
Byiers, S.6
Shao, Q.7
Dejager, S.8
-
106
-
-
65549123794
-
Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: A randomized controlled trial
-
Jadzinsky M, Pfützner A, Paz-Pacheco E, Xu Z, Allen E, Chen R. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009. 11:611-622.
-
(2009)
Diabetes Obes Metab
, vol.11
, pp. 611-622
-
-
Jadzinsky, M.1
Pfützner, A.2
Paz-Pacheco, E.3
Xu, Z.4
Allen, E.5
Chen, R.6
-
107
-
-
69549135336
-
The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone
-
DeFronzo RA, Hissa MN, Garber AJ, Luiz Gross J, Yuyan Duan R, Ravichandran S, Chen RS. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009. 32:1649-1655.
-
(2009)
Diabetes Care
, vol.32
, pp. 1649-1655
-
-
Defronzo, R.A.1
Hissa, M.N.2
Garber, A.J.3
Luiz, G.J.4
Yuyan, D.R.5
Ravichandran, S.6
Chen, R.S.7
-
108
-
-
34547863123
-
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin
-
Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007. 9:733-745.
-
(2007)
Diabetes Obes Metab
, vol.9
, pp. 733-745
-
-
Hermansen, K.1
Kipnes, M.2
Luo, E.3
Fanurik, D.4
Khatami, H.5
Stein, P.6
-
109
-
-
54249106294
-
Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea
-
Garber AJ, Foley JE, Banerji MA, Ebeling P, Gudbjörnsdottir S, Camisasca RP, Couturier A, Baron MA. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab 2008. 10:1047-1056.
-
(2008)
Diabetes Obes Metab
, vol.10
, pp. 1047-1056
-
-
Garber, A.J.1
Foley, J.E.2
Banerji, M.A.3
Ebeling, P.4
Gudbjörnsdottir, S.5
Camisasca, R.P.6
Couturier, A.7
Baron, M.A.8
-
110
-
-
68949212458
-
Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: A randomised controlled trial
-
Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract 2009. 63:1395-1406.
-
(2009)
Int J Clin Pract
, vol.63
, pp. 1395-1406
-
-
Chacra, A.R.1
Tan, G.H.2
Apanovitch, A.3
Ravichandran, S.4
List, J.5
Chen, R.6
-
111
-
-
33751557143
-
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
-
Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006. 28:1556-1568.
-
(2006)
Clin Ther
, vol.28
, pp. 1556-1568
-
-
Rosenstock, J.1
Brazg, R.2
Andryuk, P.J.3
Lu, K.4
Stein, P.5
-
112
-
-
33846828660
-
Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: A randomized, placebo-controlled study
-
Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007. 9:166-174.
-
(2007)
Diabetes Obes Metab
, vol.9
, pp. 166-174
-
-
Garber, A.J.1
Schweizer, A.2
Baron, M.A.3
Rochotte, E.4
Dejager, S.5
-
113
-
-
73149084956
-
Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone
-
Hollander P, Li J, Allen E, Chen R. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab 2009. 94:4810-4819.
-
(2009)
J Clin Endocrinol Metab
, vol.94
, pp. 4810-4819
-
-
Hollander, P.1
Li, J.2
Allen, E.3
Chen, R.4
-
114
-
-
79959217544
-
Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus
-
Hollander PL, Jia Li, Frederich R, Allen E, Chen R. Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus. Diab Vasc Dis Res 2011. 8:125-135.
-
(2011)
Diab. Vasc Dis Res
, vol.8
, pp. 125-135
-
-
Hollander, P.L.1
Jia, L.2
Frederich, R.3
Allen, E.4
Chen, R.5
-
115
-
-
34247874561
-
Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes
-
Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007. 50:1148-1155.
-
(2007)
Diabetologia
, vol.50
, pp. 1148-1155
-
-
Fonseca, V.1
Schweizer, A.2
Albrecht, D.3
Baron, M.A.4
Chang, I.5
Dejager, S.6
-
116
-
-
73349119110
-
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
-
Ling Y, Kaufman KD, Amatruda JM, Engel SS, Katz L. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2010. 12:167-177.
-
(2010)
Diabetes Obes Metab
, vol.12
, pp. 167-177
-
-
Ling, Y.1
Kaufman, K.D.2
Amatruda, J.M.3
Engel, S.S.4
Katz, L.5
-
117
-
-
17144371646
-
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
-
Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005. 28:1083-1091.
-
(2005)
Diabetes Care
, vol.28
, pp. 1083-1091
-
-
Kendall, D.M.1
Riddle, M.C.2
Rosenstock, J.3
Zhuang, D.4
Kim, D.D.5
Fineman, M.S.6
Baron, A.D.7
-
118
-
-
34247195226
-
A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: A non-inferiority study
-
Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A, Brodows R, Trautmann M. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007. 50:259-267.
-
(2007)
Diabetologia
, vol.50
, pp. 259-267
-
-
Nauck, M.A.1
Duran, S.2
Kim, D.3
Johns, D.4
Northrup, J.5
Festa, A.6
Brodows, R.7
Trautmann, M.8
-
119
-
-
26944477362
-
Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial
-
Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005. 143:559-569.
-
(2005)
Ann Intern Med
, vol.143
, pp. 559-569
-
-
Heine, R.J.1
van Gaal, L.F.2
Johns, D.3
Mihm, M.J.4
Widel, M.H.5
Brodows, R.G.6
-
120
-
-
69949117621
-
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): A randomised controlled trial
-
Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Simo R. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009. 52:2046-2055.
-
(2009)
Diabetologia
, vol.52
, pp. 2046-2055
-
-
Russell-Jones, D.1
Vaag, A.2
Schmitz, O.3
Sethi, B.K.4
Lalic, N.5
Antic, S.6
Zdravkovic, M.7
Ravn, G.M.8
Simo, R.9
-
121
-
-
67650066860
-
Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD)
-
Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, Hale PM, Zdravkovic M, Blonde L. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009. 32:1224-1230.
-
(2009)
Diabetes Care
, vol.32
, pp. 1224-1230
-
-
Zinman, B.1
Gerich, J.2
Buse, J.B.3
Lewin, A.4
Schwartz, S.5
Raskin, P.6
Hale, P.M.7
Zdravkovic, M.8
Blonde, L.9
-
122
-
-
79956151964
-
Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: A randomized 26-week study on glycemic control and hypoglycemia
-
Gallwitz B, Böhmer M, Segiet T, Mölle A, Milek K, Becker B, Helsberg K, Petto H, Peters N, Bachmann O. Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia. Diabetes Care 2011. 34:604-606.
-
(2011)
Diabetes Care
, vol.34
, pp. 604-606
-
-
Gallwitz, B.1
Böhmer, M.2
Segiet, T.3
Mölle, A.4
Milek, K.5
Becker, B.6
Helsberg, K.7
Petto, H.8
Peters, N.9
Bachmann, O.10
-
123
-
-
70450199755
-
Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: Results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study
-
Davies MJ, Donnelly R, Barnett AH, Jones S, Nicolay C, Kilcoyne A. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes Obes Metab 2009. 11:1153-1162.
-
(2009)
Diabetes Obes Metab
, vol.11
, pp. 1153-1162
-
-
Davies, M.J.1
Donnelly, R.2
Barnett, A.H.3
Jones, S.4
Nicolay, C.5
Kilcoyne, A.6
-
124
-
-
37349008890
-
Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trial
-
Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann ME. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 2007. 29:2333-2348.
-
(2007)
Clin Ther
, vol.29
, pp. 2333-2348
-
-
Barnett, A.H.1
Burger, J.2
Johns, D.3
Brodows, R.4
Kendall, D.M.5
Roberts, A.6
Trautmann, M.E.7
-
125
-
-
77952309372
-
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: A 26-week, randomised, parallel-group, open-label trial
-
Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Thomsen AB, Sondergaard RE, Davies M. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010. 375:1447-1456.
-
(2010)
Lancet
, vol.375
, pp. 1447-1456
-
-
Pratley, R.E.1
Nauck, M.2
Bailey, T.3
Montanya, E.4
Cuddihy, R.5
Filetti, S.6
Thomsen, A.B.7
Sondergaard, R.E.8
Davies, M.9
-
126
-
-
77955573674
-
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): A randomised trial
-
Bergenstal RM, Wysham C, Macconell L, Malloy J, Walsh B, Yan P, Wilhelm K, Malone J, Porter LE. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010. 376:431-439.
-
(2010)
Lancet
, vol.376
, pp. 431-439
-
-
Bergenstal, R.M.1
Wysham, C.2
Macconell, L.3
Malloy, J.4
Walsh, B.5
Yan, P.6
Wilhelm, K.7
Malone, J.8
Porter, L.E.9
-
127
-
-
55549136417
-
Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: A randomized, cross-over study
-
DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008. 24:2943-2952.
-
(2008)
Curr Med Res Opin
, vol.24
, pp. 2943-2952
-
-
Defronzo, R.A.1
Okerson, T.2
Viswanathan, P.3
Guan, X.4
Holcombe, J.H.5
Macconell, L.6
-
128
-
-
80053390364
-
Effects of exenatide twice daily versus sitagliptin on 24-hour glucose, glucoregulatory, and hormonal measures: A randomized, double-blind, crossover study
-
In press
-
Berg JK, Shenouda SK, Heilmann CR, Gray AL, Holcombe JH. Effects of exenatide twice daily versus sitagliptin on 24-hour glucose, glucoregulatory, and hormonal measures: a randomized, double-blind, crossover study. Diabetes Obes Metab 2011. In press.
-
(2011)
Diabetes Obes Metab
-
-
Berg, J.K.1
Shenouda, S.K.2
Heilmann, C.R.3
Gray, A.L.4
Holcombe, J.H.5
-
129
-
-
68949159829
-
Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors
-
Verspohl EJ. Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther 2009. 124:113-138.
-
(2009)
Pharmacol Ther
, vol.124
, pp. 113-138
-
-
Verspohl, E.J.1
-
130
-
-
33846006173
-
The incretin system: Glucagonlike peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
-
Drucker DJ, Nauck MA. The incretin system: glucagonlike peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006. 368:1696-1705.
-
(2006)
Lancet
, vol.368
, pp. 1696-1705
-
-
Drucker, D.J.1
Nauck, M.A.2
|